Travere Therapeutics, Inc. · NASDAQ:TVTX
Travere Therapeutics — ERA Congress 2025 (Vienna & Virtual, June 4-7, 2025)
11 slides from Travere Therapeutics's conference presentation, June 2025
Slide 1: Kidney outcomes and the effect of proteinuria in Alport Syndrome
UK Kidney Association RaDaR Registry of Rare Kidney Diseases UCL in collaboration with Rare Renal CONGRESS VIENNA & VIRTUAL Osterreichische Gesellschaft OGN Nephrologie JUNE 4-7, 2025 Nephrology Kidney outcomes and the effect of proteinuria in Alport Syndrome: a longitudinal analysis usin g data fro
Slide 2: Funding and disclosures
• Alport UK • Sanofi • Travere therapeutics • Bayer 2 MA-SP-25-0098 06/2025
Slide 3: Background
Ba c kg round Alport Syndrome is the 2 nd co m m o ne st g e ne tic kidne y Age at kidney failure, stratified by genotype dise a se a nd ca n le a d to kid ne y fa ilure (KF) 1.0 Logrank p <.0001 Pre vio us g e no typ e -p he no typ e co rre la tio n stud ie s ha ve 0.8 Survival Probability fo und a
Slide 4: National Registry of Rare Kidney Diseases (RaDaR)
Na tiona l Re g istry of Ra re Kid ne y Dise a se s (Ra Da R) Data linkage IT • Recruits from >100 UK renal units UK Kidney Association UK Renal Registry systems RaDaR Registry of Rare Kidney Diseases • Began recruiting patients with Alport Syndrome in 2013 Regional genetic hubs (clinical genetic re
Slide 5: eGFR trajectory
e GFR tra je c tory Annualised eGFR slope by CKD stage, stratified by severe and heterozygous genotypes 2 Annualised eGFR slope (ml/min/1.73m2/year) 0 Severe : Male X-Linked AS, 2x COL4A3/4 variants -2 -4 Heterozygous : Female X-Linked -6 AS, COL4A3/4 heterozygotes p=0.0002 p=0.2010 p=0.6854 p=0.006
Slide 6: Annualised eGFR slope, stratified by CKD stage and genotype
Annua lise d e GFR slo p e , stra tifie d b y CKD sta g e a nd g e no typ e a) Male X-Linked AS b) Female X-Linked AS n=124 n=31 n=26 n=27 n=33 n=28 n=15 n=6 eGFR slope (ml/min/1.73m2/year) • Acceleration in -10 -10 eGFR decline in eGFR slope -12 12 CKD stage 4 for all 14 -14 genotypes -16 -16 • Tim
Slide 7: Progression of proteinuria
Prog re ssion of p rote inuria Median time averaged proteinuria, by CKD stage and stratified by genotype Male XLAS 1000 Female XLAS 006 500 450 800 400 700 TAP (mg/mmol) 350 600 500 400 300 250 200 — TAP 300 150 200 100 100 50 = CKD stage1 CKD stage2 CKDstage3a CKDstage3b 1 CKD stage CKD stage 2 CKD
Slide 8: Linear mixed model of proteinuria (UPCR) trajectory, by genotype
Line a r m ixe d m od e l of p rote inuria (UPCR) tra je c tory, b y g e notyp e 10000 2x COL4A3/4 variants p=0.0035 • Males with X-Linked AS and those Male X-Linked AS Female X-Linked AS p=0.79 with 2x COLA3/4 variants had a COL4A3/4 heterozygous variants p=0.0055 statistically significant rise in
Slide 9: Proteinuria and time to kidney failure from eGFR 90, 60, 45
Proteinuria and time to kidney failure from a) eGFR 90 b) eGFR 60 c) eGFR 45 ml/min/1.73 2 All 1192 patients recruited to Alport Syndrome cohort eGFR 90 ml/min/1.73m 2 eGFR 60 ml/min/1.73m 2 eGFR 45 ml/min/1.73m 2 1.0 1.0 1.0 Logrank p=0.0030 Logrank 0.8 0.8 0.8 Survival Probability Survival Probabi
Slide 10: Conclusions & Discussion
Conc lusions & Disc ussion We have demonstrated that • e GFR slo p e va rie s b y genotype and CKD stage • eGFR decline accelerates for all genotypes on reaching CKD stage 4 in Alport syndrome • Proteinuria progression varies by genotype • Higher proteinuria levels were significantly associated with
Slide 11: Acknowledgements
Ac know le d g e m e nts a brighter future for people living with alport syndrome All patients and families who have kindly agreed to Susie Gear participate in RaDaR Hannah Russell STONEYGATE TRUST Alport Sanofi Research Dr Shiguang Liu Renal Medicine UK Dr Pronabesh DasMahaptra Angela Branson Super
Travere Therapeutics — ERA Congress 2025 (Vienna & Virtual, June 4-7, 2025) on 6ix